Price (delayed)
$22.265
Market cap
$611.16M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$6.35
Enterprise value
$556.28M
Imsidolimab, previously known as ANB019, is an antibody that inhibits the function of the interleukin-36-receptor, or IL-36R, which AnaptysBio plans to initially develop as a potential first-in-class therapy for patients
There are no recent dividends present for ANAB.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.